登录 +0086-27-65522453 [email protected]

Elafibranor(GFT505) 编号 : 5112801

化学信息

产品英文名称Elafibranor(GFT505)
Iupac 化学名称(E)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid 
同义词GFT505,SureCN815512,GFT-505,GFT 505 
英文同义词GFT505,SureCN815512,GFT-505,GFT 505 
分子式C22H24O4S 
分子量384.49 
SmileCC(C)(OC1=C(C)C=C(/C=C/C(C2=CC=C(SC)C=C2)=O)C=C1C)C(O)=O
InChiKeyAFLFKFHDSCQHOL-IZZDOVSWSA-N
InChiInChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
Cas923978-27-2

技术数据

外观light-yellow solid 
纯度98% by HPLC at 254nm 
可溶性Soluble in DMSO 
存储3 years -20ºCpowder;6 months-80ºCin solvent 
运输条件Shipped under ambient temperature. 
质量控制 HNMR HPLC MS

产品详情

Elafibranor (GFT505) is Genfits lead pipeline product. Its an oral once-daily treatment, positioned as a first-in-class drug to treat nonalcoholic steatohepatitis (NASH). Based on the beneficial activities that it demonstrates on the different features of the pathology, Elafibranor represents the ideal drug for NASH patients, including those suffering from the most severe forms of the disease.

The new non-proprietary name, Elafibranor, reflects the first-in-class nature of the drug candidate, since it does not contain a pre-existing INN stem. The novel pre-stem -fibranor may thus become an established stem over time, as other later developed drugs are recognized to be related in structure or activity.

Phase 3 launch in 2015

In March 2015, Genfit announced topline results from the phase 2b GOLDEN-505 trial in NASH (GFT505-2127) in which Elafibranor has been tested for clinical efficacy in NASH in a 1-year liver biopsy-based Phase 2b trial (GFT505-2127), one of the largest interventional studies ever conducted in NASH:

 

结构

5112801 - Elafibranor(GFT505) | CAS 923978-27-2

包装

规格价格
登录 to get price

快速订购

Change

联系我们